Based on injury time point results alone, reducing neutrophil recruitment, activation, and subsequent hepatic damage would appear a potentially tractable therapeutic target in APAP-ALI, particularly with the horizon of more available specific FPR1 inhibitors and clinical trials in other conditions.84 Here, FPR1 is linked to acute respiratory distress syndrome.